As Congress and FTC Continue to Investigate and Address the Role of Pharma Middlemen in High Drug Costs, Leading Senators Highlight Concerning New Practices Known as “Co-Manufacturing”
Washington, D.C. – Senate Finance Committee Chair Ron Wyden, D-Ore., and Finance Committee Member Senator Sherrod Brown, D-Ohio, today urged the Federal Trade Commission (FTC) to expand its work into additional anti-competitive practices by pharmacy benefit managers (PBMs) that the industry may be using to put up barriers to competition and take in larger revenues.
Comments